RecruitingNot Applicable

Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds

China3,000 participantsStarted 2022-03-01

Plain-language summary

To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients diagnosed clinically as ischemic stroke;
✓. Age ≥ 40 years;
✓. Onset time ≤ 3 months;
✓. Informed consent was signed.

Exclusion criteria

✕. Patients with symptomatic intracranial hemorrhage;
✕. bleeding lesion \> 10 mm was found on SWI;
✕. Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present;
✕. There are contraindications for antithrombotic drugs use;
✕. Serious systemic diseases;
✕. Refusal to sign informed consent or poor compliance.

What they're measuring

Increase of cerebral microbleeds

Timeframe: 1 year after onset

Trial details

NCT IDNCT05032053

SponsorXijing Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-01

Contact for this trial

Wen Jiang, Ph.D

86-029-84771319 jiangwen@fmmu.edu.cn

View on ClinicalTrials.gov More Ischemic Stroke trials